Ocular Therapeutix’ bold vision to redefine retinal disease treatment
Pravin Dugel, CEO of Ocular Therapeutix, shares insights on retinal disease treatments, challenges...
Read (4m) | 
Listen (24m) | BioAge is translating insights from the science of aging into new medicines
As the global population grows older, demand is increasing for medicines that improve healthspan. BioAge is...
Uncertainty reigns, but opportunity persists for biotech’s 2025
Biotech is rife with innovation and opportunity in 2025, despite uncertain macroeconomic and political...
Unlocking Biotech’s Potential: Strategies for Navigating Public and Private Market Investments
How are public and private investment dynamics shaping the biotech sector as it fights to bounce back from...
Shot-on-Goal Licensing Company Aims for Breakthroughs
A very special breed of animals is helping biotech and pharma companies in the quest for new human...
Why Biopharma Needs to Tell Better Stories on Novel Drugs
Ronald Martell is a serial entrepreneur and biopharma veteran whose record includes the launch of Herceptin....
Venture capital velocity: What’s driving renewed momentum in biotech?
As biotech investment reignites, how are venture capitalists responding? Noël Brown, Head of U.S....
Pharma Understands Phase One Data – But Does the Market?
Public biotech Pyxis Oncology is taking forward its innovative work on ADCs. President and CEO, Lara...
Davern Capital sees GLP-1 Opportunities Beyond Obesity
Davern Capital’s founder, Elie Kobrin, approaches the biopharma market from a long/short perspective – but...
Innovation and an Aging Population Drive MedTech
Positive trends are driving momentum in the MedTech space, with sector fundamentals the strongest they’ve...
Biopharma Investors See Opportunities in Targeted Treatments and Gene Editing
Personalized, targeted drug therapies and novel gene editing techniques are helping researchers and...
The M&A Pool Set to Accelerate Biotech Innovation
Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But...
Pathfinders in Biopharma podcast
Our podcast series explores the fast-moving world of biopharma and what the road ahead looks like for companies and investors in the sector.
More healthcare insights
From biotech breakthroughs to digital transformation, our global healthcare specialists dive deep into the latest trends, innovations, and emerging opportunities.
Stay informed
Get the latest insights from RBC Capital Markets delivered to your inbox.